TL;DR
This study introduces a novel "disease progression score" (DPS) derived from multimodal brain imaging (amyloid PET and hippocampal volume) to better capture Alzheimer's disease (AD) progression than single-modality measures. A genome-wide association study (GWAS) using this DPS identified a novel genetic locus, LCORL, associated with AD progression, with the minor allele showing a protective effect against conversion to AD.
What Problem Does This Paper Address?
Alzheimer's disease is a complex neurodegenerative disorder with a long prodromal phase. Traditional genetic studies often rely on simple case-control classifications, which can be imprecise and miss genetic influences on the subtle, continuous changes that occur during disease development. While imaging biomarkers like amyloid burden and hippocampal atrophy are valuable, studying them in isolation might not fully capture the dynamic, multi-faceted nature of AD progression. This paper aims to address this by developing a more integrated, quantitative phenotype (the DPS) that combines information from multiple imaging modalities over time, and then using this to identify novel genetic risk factors for AD progression.
Methods
The core innovation is the Disease Progression Score (DPS). This score is derived using the GRACE algorithm, which models the longitudinal trajectories of multiple biomarkers (here, cortical amyloid burden from PET and bilateral hippocampal volume from MRI) to estimate a subject's position along a population-level disease progression curve. The DPS is essentially a time-shift parameter that aligns an individual's biomarker data with the population model, effectively quantifying how far along the disease continuum they are.
This DPS was then used as a quantitative trait in a genome-wide association study (GWAS). Standard GWAS procedures were followed, including imputation and quality control of genetic data, and controlling for relevant covariates (age, sex, APOE4 status, education, and principal components of population structure).
To validate the findings, a competing risks regression analysis was performed on an independent cohort to assess the effect of the top identified genetic variants on the risk of conversion from healthy aging or mild cognitive impairment (MCI) to AD, accounting for death as a competing event.
Datasets
- Alzheimer's Disease Neuroimaging Initiative (ADNI) database: This was the primary dataset used for developing the DPS and conducting the discovery GWAS. It includes longitudinal imaging (PET and MRI) and genetic data from subjects with AD, MCI, and healthy controls.
- National Alzheimer's Coordinating Center (NACC) database: This independent dataset was used for the validation of the top genetic findings, specifically for assessing the effect of the identified SNP on clinical conversion risk.
Key Insights and Ideas
- Multimodal DPS as a Superior Phenotype: The DPS, by integrating information from amyloid burden and hippocampal volume over time, provides a more sensitive and comprehensive measure of AD progression than single-modality biomarkers. It better separates diagnostic groups and shows stronger associations with genetic risk scores.
- Novel Locus for AD Progression: The study identified a genome-wide significant association with the LCORL gene (specifically SNP rs6850306) on chromosome 4. This is a novel finding for AD progression, suggesting a new genetic pathway involved.
- Protective Effect of LCORL Minor Allele: The minor allele of rs6850306 was found to be protective against conversion from MCI to AD, and also associated with a lower DPS. This suggests a potential therapeutic target or a marker for slower disease progression.
- LCORL as an Expression Quantitative Trait Locus (eQTL): The identified SNP rs6850306 acts as a cis-eQTL for LCORL in hippocampal tissue, meaning it influences the gene's expression levels. This provides a biological mechanism linking the genetic variant to brain function.
- Integrative Approach Potential: The paper highlights the power of combining multimodal imaging with genetic studies to uncover complex disease mechanisms, moving beyond traditional case-control designs.
Key Results
- A genome-wide significant association was found for the DPS with SNP rs6850306 on chromosome 4, with a P-value of 1.03 × 10⁻⁸.
- The minor allele of rs6850306 was found to be protective against conversion from MCI to AD in the NACC cohort (Hazard Ratio = 0.593, 95% CI = 0.387–0.907, PBonf = 0.032).
- This protective effect aligns with the negative direction of effect observed in the GWAS (βdisease progression score = -0.07 ± 0.01).
- rs6850306 was identified as a cis-eQTL for LCORL in hippocampal tissue.
- No genome-wide significant associations were found for hippocampal volume or cortical amyloid alone.
Limitations and Future Work
- Biomarker Selection: The DPS relies on the choice of biomarkers. While amyloid and hippocampal volume are key for AD, using a larger or different set of biomarkers could potentially yield more granular estimates and increase statistical power.
- Validation Cohort Size: The authors acknowledge the difficulty in validating multimodal phenotypes in independent cohorts due to the need for comprehensive genotyping and longitudinal imaging data. A formal replication cohort was not secured.
- Imaging Biomarker Variation: Imaging-derived phenotypes can introduce variability. The discrepancy in findings for a previously identified amyloid locus (rs509208) highlights the need for robust imaging biomarkers like the DPS and standardized pipelines.
- Fine-mapping and Functional Studies: While the study implicates LCORL, further fine-mapping of the genomic region and functional studies (including animal models) are needed to definitively identify the causal gene and mechanism.
- Future Directions: The authors suggest that this integrative approach has significant potential for identifying genetic drivers of complex diseases by combining multimodal imaging with genetic association studies. They advocate for further exploration of multimodal phenotypes in GWAS.
Summary updated